National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Preferred Name

Pegvisomant

Synonyms

Somatotropin (18-Aspartic Acid, 21-Asparagine, 120-Lysine, 167-Asparagine, 168-Alanine, 171-Serine, 172-Arginine, 174-Serine, 179-Threonine) (Human), Pegylated

PEGVISOMANT

Pegvisomant

Somavert

Trovert

Definitions

A pegylated, recombinant, human growth hormone (GH) structural analog with GH receptor antagonist activity. As a GH analog, the structure of pegvisomant is similar to that of native GH with the exception of 9 amino acid substitutions. Pegvisomant selectively binds to GH receptors on cell surfaces, interfering with endogenous GH receptor binding and so GH signal transduction. Inhibition of GH signal transduction results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and other GH-responsive serum proteins, including IGF binding protein-3 (IGFBP-3) and the acid-labile subunit (ALS), and may inhibit the growth of cancers in which IGF-1 is upregulated.

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C61881

CAS_Registry

218620-50-9

code

C61881

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

Contributing_Source

CTRP

FDA

GDC

DEFINITION

A pegylated, recombinant, human growth hormone (GH) structural analog with GH receptor antagonist activity. As a GH analog, the structure of pegvisomant is similar to that of native GH with the exception of 9 amino acid substitutions. Pegvisomant selectively binds to GH receptors on cell surfaces, interfering with endogenous GH receptor binding and so GH signal transduction. Inhibition of GH signal transduction results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and other GH-responsive serum proteins, including IGF binding protein-3 (IGFBP-3) and the acid-labile subunit (ALS), and may inhibit the growth of cancers in which IGF-1 is upregulated.

Display_Name

Pegvisomant

FDA_UNII_Code

N824AOU5XV

FULL_SYN

Somatotropin (18-Aspartic Acid, 21-Asparagine, 120-Lysine, 167-Asparagine, 168-Alanine, 171-Serine, 172-Arginine, 174-Serine, 179-Threonine) (Human), Pegylated

PEGVISOMANT

Pegvisomant

Somavert

Trovert

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C41017

Is_Value_For_GDC_Property

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

label

Pegvisomant

Legacy Concept Name

Pegvisomant

Maps_To

Pegvisomant

NCI_Drug_Dictionary_ID

655949

PDQ_Closed_Trial_Search_ID

655949

PDQ_Open_Trial_Search_ID

655949

Preferred_Name

Pegvisomant

prefixIRI

Thesaurus:C61881

Semantic_Type

Pharmacologic Substance

UMLS_CUI

C0913469

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63347

Delete Subject Author Type Created
No notes to display